Piper Sandler Maintains Overweight on Shockwave Medical, Raises Price Target to $360
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder has maintained an Overweight rating on Shockwave Medical (NASDAQ:SWAV) and increased the price target from $290 to $360.
April 02, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Adam Maeder has reaffirmed an Overweight rating on Shockwave Medical and raised the price target from $290 to $360.
The increase in price target by a reputable analyst like Adam Maeder from Piper Sandler suggests a strong bullish outlook on Shockwave Medical. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price of SWAV.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100